8hll - Revision history

OCA at 19:51, 29 May 2024

OCA — Wed, 29 May 2024 19:51:18 GMT

←Older revision		Revision as of 19:51, 29 May 2024
Line 9:		Line 9:
	</table>		</table>
	== Disease ==		== Disease ==
-	[https://www.uniprot.org/uniprot/~~P53_HUMAN P53_HUMAN~~] Note=~~TP53 is~~ found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic ~~gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma~~. ~~Defects in TP53 are a cause of esophageal cancer~~ (~~ESCR~~) ~~[MIM:[https://omim.org/entry/133239 133239]. Defects in TP53 are a cause of Li-Fraumeni syndrome~~ (~~LFS~~) [MIM:[https://omim.org/entry/151623 151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with ~~a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age~~. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.<ref>PMID:10570149</ref> <ref>PMID:1933902</ref> <ref>PMID:1978757</ref> <ref>PMID:2259385</ref> <ref>PMID:1737852</ref> <ref>PMID:1565144</ref> <ref>PMID:7887414</ref> <ref>PMID:8825920</ref> <ref>PMID:9452042</ref> <ref>PMID:10484981</ref> Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) [MIM:[https://omim.org/entry/275355 275355]; also known as squamous cell carcinoma of the head and neck. Defects in TP53 are a cause of lung cancer (LNCR) [MIM:[https://omim.org/entry/211980 211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-~~small cell lung cancer (NSCLC) that can~~ be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:[https://omim.org/entry/260500 260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood.<ref>PMID:12085209</ref> Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:[https://omim.org/entry/202300 202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni syndrome.<ref>PMID:11481490</ref> Defects in TP53 are the cause of susceptibility to basal cell carcinoma 7 (BCC7) [MIM:[https://omim.org/entry/614740 614740]. A common malignant skin neoplasm that typically appears on hair-bearing skin, most commonly on sun-exposed areas. It is slow growing and rarely metastasizes, but has potentialities for local invasion and destruction. It usually develops as a flat, firm, pale area that is small, raised, pink or red, translucent, shiny, and waxy, and the ~~area may bleed following minor injury. Tumor size can vary from a few millimeters to several centimeters~~ in ~~diameter~~.~~<ref>PMID:21946351</ref>~~	+	[https://www.uniprot.org/uniprot/BCL2_HUMAN BCL2_HUMAN] Note=A chromosomal aberration involving BCL2 has been found in chronic lymphatic leukemia. Translocation t(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutations found in non-Hodgkin lymphomas carrying the chromosomal translocation could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions.
	== Function ==		== Function ==
-	[https://www.uniprot.org/uniprot/~~P53_HUMAN P53_HUMAN~~] ~~Acts as a tumor suppressor in many tumor types; induces growth arrest or~~ apoptosis ~~depending on the physiological circumstances and cell type. Involved~~ in cell ~~cycle regulation as a trans~~-~~activator that acts to negatively regulate~~ cell ~~division~~ by controlling ~~a set of genes required for this process. One of~~ the ~~activated genes is an inhibitor of cyclin-dependent kinases~~. ~~Apoptosis induction seems~~ to ~~be mediated~~ either by ~~stimulation~~ of ~~BAX~~ and ~~FAS antigen expression,~~ or by ~~repression of Bcl~~-~~2 expression. In cooperation with mitochondrial PPIF is involved in~~ activating ~~oxidative stress~~-~~induced necrosis~~; ~~te function~~ is ~~largely independent~~ of transcription. ~~Induces~~ the ~~transcription~~ of ~~long intergenic non~~-~~coding RNA p21 (lincRNA~~-~~p21) and lincRNA~~-~~Mkln1~~. ~~LincRNA~~-~~p21 participates in TP53~~-~~dependent transcriptional repression leading to apoptosis~~ and ~~seem to have to effect on cell~~-~~cycle regulation. Implicated~~ in ~~Notch signaling cross~~-~~over~~. ~~Prevents CDK7 kinase activity when associated to CAK~~ complex in ~~response to DNA damage, thus stopping~~ cell ~~cycle progression~~. ~~Isoform~~ 2 ~~enhances~~ the ~~transactivation activity~~ of ~~isoform 1 from some but not all TP53~~-~~inducible promoters~~. ~~Isoform 4 suppresses transactivation~~ activity ~~and impairs growth suppression mediated by isoform 1~~. ~~Isoform 7 inhibits isoform~~ 1~~-mediated apoptosis~~.~~<ref>PMID~~:~~9840937<~~/~~ref> <ref>~~PMID:~~11025664</ref>~~ <ref>PMID:~~12810724~~</ref> ~~<ref>PMID:15186775<~~/~~ref>~~ <~~ref~~>~~PMID:15340061~~</~~ref~~> <~~ref>PMID~~:~~17317671</ref~~> ~~<ref>PMID:17349958~~</~~ref> <ref>PMID:19556538</ref> <ref>PMID:20673990</ref> <ref>PMID:20959462</ref> <ref>PMID:22726440</ref~~>	+	[https://www.uniprot.org/uniprot/BCL2_HUMAN BCL2_HUMAN] Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1).<ref>PMID:18570871</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Mitochondrial apoptosis is strictly controlled by BCL-2 family proteins through a subtle network of protein interactions. The tumor suppressor protein p53 triggers transcription-independent apoptosis through direct interactions with BCL-2 family proteins, but the molecular mechanism is not well understood. In this study, we present three crystal structures of p53-DBD in complex with the anti-apoptotic protein BCL-2 at resolutions of 2.3-2.7 A. The structures show that two loops of p53-DBD penetrate directly into the BH3-binding pocket of BCL-2. Structure-based mutations at the interface impair the p53/BCL-2 interaction. Specifically, the binding sites for p53 and the pro-apoptotic protein Bax in the BCL-2 pocket are mostly identical. In addition, formation of the p53/BCL-2 complex is negatively correlated with the formation of BCL-2 complexes with pro-apoptotic BCL-2 family members. Defects in the p53/BCL-2 interaction attenuate p53-mediated cell apoptosis. Overall, our study provides a structural basis for the interaction between p53 and BCL-2, and suggests a molecular mechanism by which p53 regulates transcription-independent apoptosis by antagonizing the interaction of BCL-2 with pro-apoptotic BCL-2 family members.
		+
		+	Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity.,Wei H, Wang H, Wang G, Qu L, Jiang L, Dai S, Chen X, Zhang Y, Chen Z, Li Y, Guo M, Chen Y Nat Commun. 2023 Jul 18;14(1):4300. doi: 10.1038/s41467-023-40087-2. PMID:37463921<ref>PMID:37463921</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 8hll" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[P53 3D structures\|P53 3D structures]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 12:39, 26 July 2023

OCA — Wed, 26 Jul 2023 12:39:42 GMT

←Older revision		Revision as of 12:39, 26 July 2023
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 8hll is ~~ON HOLD until 2024~~-11-30	+	==Crystal structure of p53/BCL2 fusion complex (complex 1)==
-		+	<StructureSection load='8hll' size='340' side='right'caption='[[8hll]], [[Resolution\|resolution]] 2.62Å' scene=''>
-	~~Authors~~: ~~Wei~~, H., ~~Guo~~, M., ~~Wang~~, H., ~~Chen~~, Y.	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[8hll]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8HLL OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8HLL FirstGlance]. <br>
-	~~Description~~: ~~Crystal structure of p53~~/~~BCL2 fusion complex~~ (complex 1)	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.62Å</td></tr>
-	[[Category: ~~Unreleased Structures~~]]	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
-	[[Category: ~~Guo, M~~]]	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8hll FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8hll OCA], [https://pdbe.org/8hll PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8hll RCSB], [https://www.ebi.ac.uk/pdbsum/8hll PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8hll ProSAT]</span></td></tr>
-	[[Category: ~~Wei, H~~]]	+	</table>
-	[[Category: ~~Chen, Y~~]]	+	== Disease ==
-	[[Category: Wang, H]]	+	[https://www.uniprot.org/uniprot/P53_HUMAN P53_HUMAN] Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma. Defects in TP53 are a cause of esophageal cancer (ESCR) [MIM:[https://omim.org/entry/133239 133239]. Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:[https://omim.org/entry/151623 151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.<ref>PMID:10570149</ref> <ref>PMID:1933902</ref> <ref>PMID:1978757</ref> <ref>PMID:2259385</ref> <ref>PMID:1737852</ref> <ref>PMID:1565144</ref> <ref>PMID:7887414</ref> <ref>PMID:8825920</ref> <ref>PMID:9452042</ref> <ref>PMID:10484981</ref> Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) [MIM:[https://omim.org/entry/275355 275355]; also known as squamous cell carcinoma of the head and neck. Defects in TP53 are a cause of lung cancer (LNCR) [MIM:[https://omim.org/entry/211980 211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:[https://omim.org/entry/260500 260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood.<ref>PMID:12085209</ref> Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:[https://omim.org/entry/202300 202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni syndrome.<ref>PMID:11481490</ref> Defects in TP53 are the cause of susceptibility to basal cell carcinoma 7 (BCC7) [MIM:[https://omim.org/entry/614740 614740]. A common malignant skin neoplasm that typically appears on hair-bearing skin, most commonly on sun-exposed areas. It is slow growing and rarely metastasizes, but has potentialities for local invasion and destruction. It usually develops as a flat, firm, pale area that is small, raised, pink or red, translucent, shiny, and waxy, and the area may bleed following minor injury. Tumor size can vary from a few millimeters to several centimeters in diameter.<ref>PMID:21946351</ref>
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/P53_HUMAN P53_HUMAN] Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; te function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.<ref>PMID:9840937</ref> <ref>PMID:11025664</ref> <ref>PMID:12810724</ref> <ref>PMID:15186775</ref> <ref>PMID:15340061</ref> <ref>PMID:17317671</ref> <ref>PMID:17349958</ref> <ref>PMID:19556538</ref> <ref>PMID:20673990</ref> <ref>PMID:20959462</ref> <ref>PMID:22726440</ref>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Homo sapiens]]
		+	[[Category: Large Structures]]
		+	[[Category: Chen Y]]
		+	[[Category: Guo M]]
		+	[[Category: Wang H]]
		+	[[Category: Wei H]]

OCA at 06:08, 11 January 2023

OCA — Wed, 11 Jan 2023 06:08:17 GMT

←Older revision		Revision as of 06:08, 11 January 2023
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 8hll is ON HOLD	+	The entry 8hll is ON HOLD until 2024-11-30

	Authors: Wei, H., Guo, M., Wang, H., Chen, Y.		Authors: Wei, H., Guo, M., Wang, H., Chen, Y.

OCA: Protected "8hll" [edit=sysop:move=sysop]

OCA — Wed, 07 Dec 2022 06:01:03 GMT

Protected "8hll" [edit=sysop:move=sysop]

←Older revision

Revision as of 06:01, 7 December 2022

OCA: New page: '''Unreleased structure''' The entry 8hll is ON HOLD Authors: Wei, H., Guo, M., Wang, H., Chen, Y. Description: Crystal structure of p53/BCL2 fusion complex (complex 1) [[Category: Unr...

OCA — Wed, 07 Dec 2022 06:01:00 GMT

New page: '''Unreleased structure''' The entry 8hll is ON HOLD Authors: Wei, H., Guo, M., Wang, H., Chen, Y. Description: Crystal structure of p53/BCL2 fusion complex (complex 1) [[Category: Unr...

New page

'''Unreleased structure'''

The entry 8hll is ON HOLD

Authors: Wei, H., Guo, M., Wang, H., Chen, Y.

Description: Crystal structure of p53/BCL2 fusion complex (complex 1)
[[Category: Unreleased Structures]]
[[Category: Guo, M]]
[[Category: Wei, H]]
[[Category: Chen, Y]]
[[Category: Wang, H]]